Healthcare (SH:603313) EBSCN·2025-10-31 08:24Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a revenue of 6.76 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 10.3%, and a net profit attributable to shareholders of 160 million yuan, marking a turnaround from losses [5][6] - The company is experiencing steady growth in both domestic and international sales, with significant performance in online channels [6][11] - The report highlights the company's strategic advantages in global layout and anticipates profit elasticity release as macro demand recovers [12] Revenue Performance - In Q1, Q2, and Q3 of 2025, the company reported revenues of 2.04 billion, 2.27 billion, and 2.44 billion yuan respectively, with year-on-year growth rates of 12.3%, 6.8%, and 12.0% [5] - Domestic sales reached 1.17 billion yuan, while international sales were 5.37 billion yuan, with year-on-year growth of 11.6% and 9.3% respectively [6] Profitability - The gross margin for the first three quarters of 2025 was 39.5%, an increase of 2.3 percentage points year-on-year [8] - The gross margin for domestic sales was 52.2%, reflecting a year-on-year increase of 6.3 percentage points [9] Future Outlook - The report projects net profits of 220 million yuan and 400 million yuan for 2025 and 2026 respectively, with corresponding EPS of 0.38 yuan and 0.70 yuan [12][13] - The company is expected to benefit from the optimization of store operations and the stabilization of overseas online business, leading to improved profitability [12]